Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation and Expansion Study of Relatlimab With and Without Nivolumab in Advanced Solid Tumors
2023-508067-70-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, open-label trial of relatlimab and nivolumab in Cervical Cancer (CC), ovarian cancer, bladder cancer and 7 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Proportion of subjects with Adverse Events (AEs), Proportion of subjects with Serious Adverse Events (SAEs) and 9 more. Started Feb 2024; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
Cervical Cancer (CC)ovarian cancerbladder cancercolorectal cancer (CRC)head and neck cancer (HNC)
Beyond the preview
Go deeper on 2023-508067-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508067-70-00.